Federated Hermes Inc. Has $474.09 Million Position in Pfizer Inc. $PFE

Federated Hermes Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 2.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,606,460 shares of the biopharmaceutical company’s stock after selling 512,479 shares during the quarter. Pfizer comprises 0.8% of Federated Hermes Inc.’s holdings, making the stock its 20th biggest position. Federated Hermes Inc. owned approximately 0.33% of Pfizer worth $474,093,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Citizens National Bank Trust Department increased its position in shares of Pfizer by 0.9% during the second quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares in the last quarter. Peak Asset Management LLC increased its holdings in Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares in the last quarter. Community Bank & Trust Waco Texas raised its stake in shares of Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares during the period. Able Wealth Management LLC lifted its holdings in shares of Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Finally, CVA Family Office LLC boosted its position in shares of Pfizer by 3.3% during the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 413 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 2.4%

PFE stock opened at $26.49 on Wednesday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The business’s 50 day simple moving average is $25.43 and its 200 day simple moving average is $25.01. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $150.61 billion, a PE ratio of 15.40 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio is presently 100.00%.

Wall Street Analyst Weigh In

Several research firms have commented on PFE. HSBC restated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Wolfe Research set a $24.00 price objective on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Scotiabank assumed coverage on shares of Pfizer in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.06.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE to $27 from $24, providing an immediate buy-side catalyst that helped lift the stock. Why Is Pfizer Stock Rising Tuesday?
• Neutral Sentiment: Market commentary and analyst notes reiterate interest in PFE after the move; some analysts continue to debate valuation and targets, producing mixed near-term signals. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Opinion pieces and bulls (e.g., Seeking Alpha) argue long-term upside tied to portfolio diversification and pipeline execution, but these are forward-looking views rather than near-term drivers. Pfizer: The Great Healthcare Plan…
• Negative Sentiment: The U.S. Centers for Medicare & Medicaid Services added several Pfizer drugs to the next round of Medicare Drug Price Negotiations (including first Part B reimbursements), which could pressure pricing and revenues if negotiations force lower prices. US Medicare names Eli Lilly, Pfizer and AbbVie drugs…
• Negative Sentiment: Earnings previews warn Q4 results may decline versus prior periods, highlighting the risk of an earnings miss or softer guidance that could weigh on the stock. Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
• Negative Sentiment: Competitive risk: Aclaris reported a hair-loss candidate that showed faster results than Pfizer’s Litfulo in preclinical tests, an early sign of therapeutic competition in a growth area. Aclaris Hair Loss Drug Shows Faster Results…
• Negative Sentiment: Wider structural concerns persist: commentary notes underperformance versus peers due to softer COVID-era product demand and an upcoming patent cliff, which are longer-term headwinds for growth. Pfizer vs. Merck Stock And JNJ
• Negative Sentiment: Balance-sheet note: analysis highlighting heavier debt usage may concern income-focused or risk-sensitive investors monitoring leverage and cash-flow resilience. These 4 Measures Indicate That Pfizer Is Using Debt Extensively

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.